

REMARKS:

Claims 2 and 15-17 are in the case and presented for consideration.

Claim 2 has been amended to highlight the distinction between the presently claimed invention and the cited reference.

Rejection Under 35 U.S.C. §102(b)

Claims 2 and 15-17 were rejected under 35 U.S.C. §102(b) as being anticipated by Hewett et al. "Cytokinins in Populus x robusta", Planta (1973) 114(2), 119-29 ("Hewett et al.").

The Office notes that Hewett et al. discloses 6-(2-hydroxybenzylamino)purine riboside.

Rejection Under 35 U.S.C. §103

Claims 2 and 15-17 were also rejected under 35 U.S.C. §103 as obvious in view of Hewett et al.

The Office notes that Hewett et al. discloses 6-(2-hydroxybenzylamino)purine riboside, rendering the claim obvious for containing this compound, as well as its positional isomers, 6-(3-hydroxybenzylamino)purine riboside and 6-(4-hydroxybenzylamino)purine riboside.

Claim 2 has been amended to clarify that it neither contains any of the compounds

disclosed in Hewett et al., nor any positional isomers thereof.

Therefore, because Hewett et al. fails to disclose or suggest elements of currently amended independent claim 2, from which claims 15-17 depend, it does not anticipate any of the claims currently in the case.

Conclusion

Accordingly, Applicants believe that all the claims are now in condition for allowance and favorable action is respectfully requested. Should there be any issues that have not been addressed to the Examiner's satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, please charge such fees to Deposit Account No. 14-1431.

Respectfully submitted,
/NADER A. ABADIR/
Nader A. Abadir
Reg. No. 52,537
Attorney for Applicants
(845) 359-7700

Dated: September 8, 2010

NOTARO & MICHALOS P.C.
100 Dutch Hill Road, Suite 110
Orangeburg, New York 10962-2100

Customer No. 21706

R:\PATAMD\J507-005\J507-005-AMD4.wpd